Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

An international research team has conceived a dual-component controller for three-phase inverters that can reportedly ...

Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...

Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

An additional two Electric Train Service (ETS) sets are expected to arrive in Malaysia in April, and be operational by August ...